Centessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Sells $163,400.00 in Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) insider Gregory M. Weinhoff sold 10,000 shares of the business’s stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $16.34, for a total transaction of $163,400.00. Following the sale, the insider now owns 134,021 shares in the company, valued at $2,189,903.14. The trade was a 6.94 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Centessa Pharmaceuticals Price Performance

Centessa Pharmaceuticals stock traded down $1.27 during midday trading on Wednesday, reaching $14.54. 2,499,419 shares of the company were exchanged, compared to its average volume of 537,096. The company has a market capitalization of $1.92 billion, a price-to-earnings ratio of -9.50 and a beta of 1.54. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. The firm’s 50-day simple moving average is $16.51 and its 200-day simple moving average is $16.43. Centessa Pharmaceuticals plc has a 1 year low of $7.75 and a 1 year high of $19.09.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its earnings results on Monday, March 24th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.04. On average, analysts anticipate that Centessa Pharmaceuticals plc will post -1.6 EPS for the current year.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. purchased a new position in Centessa Pharmaceuticals in the fourth quarter valued at approximately $31,000. GAMMA Investing LLC boosted its holdings in Centessa Pharmaceuticals by 29.1% in the fourth quarter. GAMMA Investing LLC now owns 3,837 shares of the company’s stock valued at $64,000 after purchasing an additional 865 shares during the last quarter. Barclays PLC increased its holdings in Centessa Pharmaceuticals by 1,414.9% during the 4th quarter. Barclays PLC now owns 5,302 shares of the company’s stock worth $89,000 after purchasing an additional 4,952 shares during the last quarter. BNP Paribas Financial Markets acquired a new position in shares of Centessa Pharmaceuticals in the 4th quarter valued at approximately $162,000. Finally, OMERS ADMINISTRATION Corp purchased a new position in shares of Centessa Pharmaceuticals during the 4th quarter valued at approximately $171,000. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on CNTA. Guggenheim restated a “buy” rating and issued a $28.00 price target on shares of Centessa Pharmaceuticals in a report on Wednesday. Morgan Stanley reissued an “overweight” rating and issued a $27.00 price objective on shares of Centessa Pharmaceuticals in a research note on Friday, March 7th. Finally, TD Cowen assumed coverage on shares of Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They set a “buy” rating for the company. Seven analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $26.00.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.